This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
An updated look at Atrasentan and BION-301's potential in treating patients with IgA Nephropathy
Ticker(s): KDNYWho's the expert?
Institution: University of Leicester
- The Mayer Professor of Renal Medicine at the University of Leicester.
- IGA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the International IgA Nephropathy Network.
- Chief Investigator for five international randomised controlled clinical trials in IgA nephropathy; attended both the FDA and EMA as an expert witness for new therapies in IgA nephropathy.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
